CytRx (CYTR) Receives EPO Patent for Linker Platform; Giver 'Aldoxorubucin' Name to INNO-206
Tweet Send to a Friend
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


